Global Multiple Myeloma Partnering 2010 to 2016; New Report Launched


Posted September 7, 2016 by drugpipeline

DrugPipeline.net has announced the addition of “Global Multiple Myeloma Partnering 2010 to 2016” research report to their website DrugPipeline.net
 
The Multiple Myeloma Partnering 2010-2015 report provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in multiple myeloma partnering deals
Top multiple myeloma deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Description
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.

Trends in partnering deals
Top deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Benefits
Global Therapy Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:

In-depth understanding of deal trends since 2010
Access to headline, upfront, milestone and royalty data
Comprehensive access to multiple deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 150 pages “Global Multiple Myeloma Partnering 2010 to 2016” report covers Therapypartnering trends in numbers, Most active dealmakers, Partnering deals directory, Partnering deals with a contract document, SEARCH.THERAPY_AREA M&A in numbers, M&A deals directory, Financing in numbers, Financing deals directory.

For more information Visit at: http://www.drugpipeline.net/current-partnering/global-multiple-myeloma-partnering-2010-2016

Related Reports:

Global Obstetrics Partnering 2010-2016: Deal trends, players and financials; visit - http://www.drugpipeline.net/current-partnering/global-obstetrics-partnering-2010-2016-deal-trends-players-and-financials

Spectrum Pharmaceuticals Partnering Deals and Alliances 2010 to 2016; visit - http://www.drugpipeline.net/current-partnering/spectrum-pharmaceuticals-partnering-deals-and-alliances-2010-2016

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr. Sudeep Chakravarty
Website DrugPipeline.net
Phone +91-8762746600
Country India
Categories Health
Tags biotechnology , pharma and healthcare
Last Updated September 7, 2016